# Court Allows Drugmakers to Join 340B Pilot Case

A federal judge allowed PhRMA and three drugmakers—Bristol Myers Squibb, AbbVie, and Boehringer Ingelheim—to intervene in litigation over HRSA’s 340B Rebate Model Pilot Program, reversing an earlier denial of their participation. The pilot is slated to begin Jan. 1, and the litigation could affect its implementation and rebate policies for participating drugmakers and hospitals.

- The ruling allows the trade association and manufacturers to participate in the case; it does not itself resolve the dispute over the pilot.
- Hospitals and drugmakers involved in the pilot should account for potential changes to implementation and rebate policies when planning drug purchasing and related financial assumptions.
- For healthcare procurement teams, the case is relevant to the terms and cost assumptions used in purchasing arrangements connected to the 340B program.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Regulatory Compliance
**Published:** October 22, 2026

### Government Entities
- U.S. Health Resources & Services Administration (HRSA)
- U.S. Department of Health and Human Services (HHS)

### Vendors
- Bristol Myers Squibb Co. (Pharmaceutical manufacturer and litigation intervenor)
- AbbVie Inc. (Pharmaceutical manufacturer and litigation intervenor)
- Boehringer Ingelheim (Pharmaceutical manufacturer and litigation intervenor)